• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Rules of the Game: Biotechs in Rally Mode

Here are two quality names in the sector to watch for a pullback.
By KATE STALTER Apr 26, 2013 | 06:00 PM EDT
Stocks quotes in this article: UTHR, BIIB

In my most recent column, I highlighted two info tech stocks that have rebounded to multiyear highs. Asset manager Gennady Kupershteyn of Kupershteyn Advisory Group pointed me toward these stocks. He noted that investors should avoid chasing too much price growth and instead pay attention to valuations at these levels.

For investors who are accustomed to scouting for value, the idea of buying a momentum stock at new highs is laughable, to put it nicely. But for momentum and growth investors, and those who simply don't want to be left out of an uptrend, it's not out of the question to buy a stock as it's soaring to new heights.

The problem is, a correction -- or at least a pullback -- always follows an uptrend. If a stock zooms higher after earnings, or as it just follows along with the general market direction, profit-taking is usually fairly close behind. This is what Kupershteyn is hoping to warn momentum traders and investors about.

Of the stocks he identified, there was a preponderance of names from the medical and info tech sectors.

United Therapeutics (UTHR) is a mid-cap biotech stock that's trading near its best levels since June 2011. On Thursday, it had one of those split-personality days. The company reported earnings that missed estimates, sending the stock into an opening-bell gap-down. However, revenue beat expectations, so the stock gradually trended higher throughout the session, as investors and traders digested the news.

United Therapeutics finished at $61.67, down 2.5% on the session but still holding 2.4% above its 50-day average.

The stock recently moved out of a fairly shallow correction, and for technical traders, it could be in a potential buy zone. For those who have a longer-term viewpoint, consider the fundamental case. The price-to-earnings ratio is 11, much lower than the biotech industry average of 64. That's a good sign, particularly in an industry that is home to many speculative stocks that don't have any revenue or earnings to speak of.

I realize that biotechs often hold appeal as potential acquisition targets, and there is also the gamble that a therapy will have good clinical results and get FDA approval. United Therapeutics is light years beyond that kind of stock; the company makes treatments for cardiovascular ailments, cancers and infectious diseases. It has been profitable in eight of the past 10 years, and annual earnings growth has accelerated for the past three years.

Some large-cap biotechs also showed up on Kupershteyn's screen. Most of these are names I've been tracking for quite some time on my growth screens as well.

One of those, Biogen Idec (BIIB), reported earnings before the market open on Thursday. The company develops treatments for autoimmune inflammatory conditions, multiple sclerosis and cancer. The stock leapt 4.8% Thursday, after a first-quarter earnings beat and an increase in its full-year earnings outlook.

It finished Thursday at $216, an all-time closing high. This is an excellent example of a stock that's trading at some lofty levels at the moment but holds potential for investors who are willing to be patient.

The P/E ratio is 35.8, so it could be considered expensive. This is why it's best to keep this stock on a watch list and wait for the inevitable pullback. Whether it's pegged to market action or simply profit-taking in the stock, it doesn't matter. Biogen is widely held, being an S&P 500 component that moves more than 1.3 million shares per day on average. In other words, there is good liquidity here, and it would not be surprising to see index action as the catalyst for the next significant pullback in the stock. That could well be the next buying opportunity.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Johnson & Johnson Appears to Be Running Out of Steam

Bruce Kamich
Jun 22, 2022 8:25 AM EDT

The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.

Anthem's Long-Term Uptrend Is Losing Its Vigor

Bruce Kamich
Jun 22, 2022 7:40 AM EDT

The technical signals of the health benefits provider are weakening.

Here Are 2 Prudent Healthcare Trades

Bret Jensen
Jun 17, 2022 11:30 AM EDT

The country might be heading into recession, but folks still need to get their medicine, good times or bad.

Here's the Level to Zero In on for UnitedHealth Group

Bruce Kamich
Jun 13, 2022 7:29 AM EDT

Shares of the diversified healthcare company have held up fairly well despite the decline in the broader market but soon could be put to the test.

3 Dividend-Paying Healthcare Stocks That Age Well

Bob Ciura
Jun 5, 2022 12:30 PM EDT

Within the next 15 years, people 65 or older are expected outnumber those under 18, for the first time in U.S. history.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:10 AM EDT PAUL PRICE

    More Insider Buying in American Woodmark (AMWD)

    American Woodmark , which I've discussed here fr...
  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • 12:08 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    As a Portfolio Name Agrees to a Merger, Here's Our...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login